Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra. Novo Nordisk’s American depositary receipts tumbled almost 6% ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Searching for the best Fiji resorts for your dream tropical escape in 2024? Fiji is a world-renowned paradise, known for its pristine private beaches, luxury spas, and exhilarating adventures. Whether ...

In January 1998 the Fiji Broadcasting Commission was corporatised under the Government’s public sector reform programme and renamed Island Network Corporation Limited. In June 1999, the change in ...